This company has been acquired
Myovant Sciences Management
Management criteria checks 4/4
Key information
Dave Marek
Chief executive officer
US$6.2m
Total compensation
CEO salary percentage | 12.0% |
CEO tenure | 2.2yrs |
CEO ownership | 0.1% |
Management average tenure | 4.3yrs |
Board average tenure | 3.3yrs |
Recent management updates
Recent updates
Myovant Sciences GAAP EPS of -$0.56 beats by $0.08, revenue of $100.23M misses by $2.13M
Jan 26Not The Buyout Offer That Myovant Shareholders Hoped For
Oct 25Myovant Sciences rejects Sumitovant Biopharma's $22.75/share takeover offer
Oct 03Women Can Thank Pfizer And Myovant For MYFEMBREE
Sep 20Myovant Sciences: Regulatory Overhang Cleared
Aug 29Myovant Sciences upgraded to outperform at SVB following additional Myfembree indication
Aug 09Myovant stock gains ~6% after hours on Q1 revenue jump
Jul 27Myovant Makes Commercial Progress As It Waits For FDA Decision On Myfembree
Jul 18Analyst Forecasts For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Apr 28Myovant: Poised To Overcome Regulatory Issues
Apr 26Regulatory Setback Brings Myovant Sciences Stock To Attractive Levels
Apr 13Myovant: Approved Drugs And Upcoming Catalysts Make This A Great Long-Term Play
Mar 26Myovant: Catalysts Powering More Upside
Jan 02Myovant Sciences: Becoming A Blockbuster
Jun 02Myovant Sciences rises on FDA approval for relugolix
May 26Analysts Just Shipped A Substantial Upgrade To Their Myovant Sciences Ltd. (NYSE:MYOV) Estimates
May 14Why The Misunderstood Pfizer Deal Makes Myovant A Great Low-Risk Investment
May 09New Forecasts: Here's What Analysts Think The Future Holds For Myovant Sciences Ltd. (NYSE:MYOV)
Feb 17Earnings Update: Myovant Sciences Ltd. (NYSE:MYOV) Just Reported And Analysts Are Boosting Their Estimates
Feb 13Analysts' Revenue Estimates For Myovant Sciences Ltd. (NYSE:MYOV) Are Surging Higher
Jan 12Myovant cut to neutral at Goldman Sachs on ‘lack of driving catalysts’
Jan 06Myovant Sciences announces distribution of ORGOVYX in the U.S.
Jan 05Myovant Sciences gains 22% on relugolix deal with Pfizer
Dec 28Have Insiders Been Selling Myovant Sciences Ltd. (NYSE:MYOV) Shares This Year?
Dec 23Myovant Sciences’ FDA win leads to Bullish views at Baird
Dec 21Myovant Sciences scores FDA approval for Orgovyx in prostate cancer
Dec 18Myovant Sciences (NYSE:MYOV) Shareholders Have Enjoyed A 60% Share Price Gain
Nov 18Myovant Sciences: More Than Meets The Eye
Nov 12The Sell-Off In Myovant Is Unjustified By Fundamentals
Nov 09CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2022 | n/a | n/a | -US$184m |
Sep 30 2022 | n/a | n/a | -US$190m |
Jun 30 2022 | n/a | n/a | -US$166m |
Mar 31 2022 | US$6m | US$750k | -US$206m |
Dec 31 2021 | n/a | n/a | -US$228m |
Sep 30 2021 | n/a | n/a | -US$238m |
Jun 30 2021 | n/a | n/a | -US$284m |
Mar 31 2021 | US$10m | US$151k | -US$255m |
Compensation vs Market: Dave's total compensation ($USD6.25M) is about average for companies of similar size in the US market ($USD6.53M).
Compensation vs Earnings: Dave's compensation has been consistent with company performance over the past year.
CEO
Dave Marek (57 yo)
2.2yrs
Tenure
US$6,247,509
Compensation
Mr. David C. Marek, also known as Dave, has been Director of Myovant Sciences Ltd. since January 4, 2021 and served as its Principal Executive Officer. He had been Chief Commercial Officer of Axsome Therap...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 2.2yrs | US$6.25m | 0.098% $ 2.6m | |
Principal Financial Officer | 1.5yrs | US$5.16m | 0.021% $ 559.0k | |
Chief Commercial Officer | 1.9yrs | US$3.47m | 0.022% $ 587.9k | |
General Counsel & Corporate Secretary | 5.7yrs | US$2.83m | 0.36% $ 9.6m | |
Director of Corporate Communications | no data | no data | no data | |
Senior Vice President of Human Resources | less than a year | no data | no data | |
Senior Vice President of Product Development | 6.6yrs | no data | no data | |
Chief Medical Officer | 5.7yrs | US$1.98m | 0.089% $ 2.3m | |
Head of Drug Safety & Pharmacovigilance | 5.7yrs | no data | no data | |
Senior VP of Pharmaceutical Operations & Development | 4.3yrs | no data | no data |
4.3yrs
Average Tenure
52yo
Average Age
Experienced Management: MYOV's management team is considered experienced (4.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO & Director | 2.2yrs | US$6.25m | 0.098% $ 2.6m | |
Chairman of the Board | 4.5yrs | US$376.79k | 0% $ 0 | |
Independent Director | 6.3yrs | US$363.33k | 0% $ 0 | |
Director | 3.3yrs | US$341.79k | 0% $ 0 | |
Lead Independent Director | 4.7yrs | US$369.95k | 0% $ 0 | |
Non Independent Director | less than a year | no data | no data | |
Independent Director | 1.3yrs | US$567.05k | 0% $ 0 |
3.3yrs
Average Tenure
59yo
Average Age
Experienced Board: MYOV's board of directors are considered experienced (3.3 years average tenure).